OptionsHouse

Options Trading News

January 11, 2013  Fri 7:36 AM CT

DNDN: SEE CHART GET CHAIN FIND STRATEGIES
Drug Maker Raised to Outperform

Dendreon was upgraded to "outperform" from "market perform" by Sanford C. Bernstein, which also raised its target price on the drug maker to $10 from $7. DNDN climbs 14 percent before the bell on my tradeMONSTER platform.

Xyratex Earnings Miss the Mark

Xyratex reported a fourth-quarter loss of $0.32, wider than the $0.24 expected by analysts. It additionally forecast first-quarter revenue of $159 million to $189 million, below the $207 million consensus estimate. XRTX is down 4 percent in the premarket.

ArQule Drops on Phase 2 Trial Results

ArQule announced that its tivantinib cancer drug failed to meet its primary endpoint in a randomized phase 2 trial. Development of the compound continues, but ARQL is down 20 percent in early trading.
Share this article with your friends


Invest Like a Monster - San Diego: June 26-27

Premium Services

Archived Webinar

Education & Strategy

Short Gamma

Last week, we talked about long Gamma. We said that long gamma is acquired by purchasing options and when you...

View more education articles »